# Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis

> **NCT00790023** · PHASE3 · COMPLETED · sponsor: **Sumitomo Pharma America, Inc.** · enrollment: 707 (actual)

## Conditions studied

- Seasonal Allergic Rhinitis

## Interventions

- **DRUG:** 80 mcg Ciclesonide
- **DRUG:** 160 mcg Ciclesonide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00790023
- **Lead sponsor:** Sumitomo Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2009-02
- **Final completion:** 2009-02
- **Target enrollment:** 707 (ACTUAL)
- **Last updated:** 2016-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00790023

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00790023, "Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT00790023. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*